Latest Breaking News On - Han si zhuang serplulimab - Page 1 : vimarsana.com

Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable. | March 28, 2023

United statesMacau generalHong kongFosun pharma artesunHan li kang rituximabGetz pharmaParsabiv etelcalcetideHan si zhuang serplulimabHan li kangFosun pharmaTridem pharmaWu yifangHan si zhuangNational medical insurance drug catalogueEuropean commissionNational reimbursement drug list